S&P 500   4,180.13 (-0.60%)
DOW   32,910.90 (-0.40%)
QQQ   348.45 (-0.44%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.63 (-0.03%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.44 (+0.40%)
BABA   79.54 (+1.11%)
AMD   118.79 (-5.17%)
T   15.81 (+1.09%)
F   12.00 (-4.69%)
MU   68.61 (-4.30%)
CGC   0.83 (-1.95%)
GE   101.39 (-0.99%)
DIS   88.13 (+0.35%)
AMC   4.52 (-2.38%)
PFE   38.11 (+2.97%)
PYPL   62.19 (+0.23%)
NFLX   394.92 (+0.49%)
S&P 500   4,180.13 (-0.60%)
DOW   32,910.90 (-0.40%)
QQQ   348.45 (-0.44%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.63 (-0.03%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.44 (+0.40%)
BABA   79.54 (+1.11%)
AMD   118.79 (-5.17%)
T   15.81 (+1.09%)
F   12.00 (-4.69%)
MU   68.61 (-4.30%)
CGC   0.83 (-1.95%)
GE   101.39 (-0.99%)
DIS   88.13 (+0.35%)
AMC   4.52 (-2.38%)
PFE   38.11 (+2.97%)
PYPL   62.19 (+0.23%)
NFLX   394.92 (+0.49%)
S&P 500   4,180.13 (-0.60%)
DOW   32,910.90 (-0.40%)
QQQ   348.45 (-0.44%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.63 (-0.03%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.44 (+0.40%)
BABA   79.54 (+1.11%)
AMD   118.79 (-5.17%)
T   15.81 (+1.09%)
F   12.00 (-4.69%)
MU   68.61 (-4.30%)
CGC   0.83 (-1.95%)
GE   101.39 (-0.99%)
DIS   88.13 (+0.35%)
AMC   4.52 (-2.38%)
PFE   38.11 (+2.97%)
PYPL   62.19 (+0.23%)
NFLX   394.92 (+0.49%)
S&P 500   4,180.13 (-0.60%)
DOW   32,910.90 (-0.40%)
QQQ   348.45 (-0.44%)
AAPL   178.91 (+0.91%)
MSFT   330.28 (-0.28%)
META   263.57 (+0.40%)
GOOGL   123.63 (-0.03%)
AMZN   120.28 (-1.13%)
TSLA   199.58 (-0.79%)
NVDA   384.26 (-4.20%)
NIO   7.44 (+0.40%)
BABA   79.54 (+1.11%)
AMD   118.79 (-5.17%)
T   15.81 (+1.09%)
F   12.00 (-4.69%)
MU   68.61 (-4.30%)
CGC   0.83 (-1.95%)
GE   101.39 (-0.99%)
DIS   88.13 (+0.35%)
AMC   4.52 (-2.38%)
PFE   38.11 (+2.97%)
PYPL   62.19 (+0.23%)
NFLX   394.92 (+0.49%)
TSE:ONC

Oncolytics Biotech (ONC) Stock Forecast, Price & News

C$2.24
-0.08 (-3.45%)
(As of 03:50 PM ET)
Compare
Today's Range
C$2.20
C$2.34
50-Day Range
C$1.51
C$2.93
52-Week Range
C$1.06
C$3.10
Volume
102,849 shs
Average Volume
54,276 shs
Market Capitalization
C$143.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$6.75

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
197.4% Upside
C$6.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.30mentions of Oncolytics Biotech in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars


ONC stock logo

About Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
TSX Sinks into the Red
Stocks in play: Oncolytics Biotech
See More Headlines
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Company Calendar

Last Earnings
3/03/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$6.75
High Stock Price Forecast
C$9.00
Low Stock Price Forecast
C$3.00
Forecasted Upside/Downside
+190.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
C$-24,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.55 per share
Book Value
C$0.40 per share

Miscellaneous

Free Float
N/A
Market Cap
C$148.69 million
Optionable
Not Optionable
Beta
1.79

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., Pres, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 55)
    Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
    Comp: $558.94k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., VP of Product Devel.
  • Jon Patton
    Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D.
    Scientist of Translational Medicine
  • Mr. John Mark Lievonen F.C.A.
    FCA, Consultant
  • Dr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)
    FACP, M.D., Consultant













ONC Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year target prices for Oncolytics Biotech's stock. Their ONC share price forecasts range from C$3.00 to C$9.00. On average, they predict the company's stock price to reach C$6.75 in the next year. This suggests a possible upside of 190.9% from the stock's current price.
View analysts price targets for ONC
or view top-rated stocks among Wall Street analysts.

How have ONC shares performed in 2023?

Oncolytics Biotech's stock was trading at C$2.22 at the beginning of the year. Since then, ONC stock has increased by 4.5% and is now trading at C$2.32.
View the best growth stocks for 2023 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ONC earnings forecast
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) posted its earnings results on Friday, March, 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.07.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$2.32.

How much money does Oncolytics Biotech make?

Oncolytics Biotech (TSE:ONC) has a market capitalization of C$148.69 million. The company earns C$-24,490,000.00 in net income (profit) each year or C($0.42) on an earnings per share basis.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at +1-403-6707380.

This page (TSE:ONC) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -